Please upgrade your browser.
Metabolism, Excretion, and Pharmacokinetics of Oral Brivanib in Patients with Advanced or Metastatic Solid Tumors
To evaluate the pharmacokinetics, mass balance, metabolism, routes and extent of elimination, and safety of a single oral dose of [(14)C]-labeled brivanib alaninate and the safety and tolerability of brivanib after multiple doses in patients with advanced or metastatic solid tumors.
The liver is an immunologically unique organ containing tolerogenic dendritic cells (DC) that maintain an immunosuppressive microenvironment. Although systemic IL-12 administration can improve responses to tumors, the effects of IL-12-based treatments on DC, in particular hepatic DC, remain incompletely understood.
New Delhi, March 12: India has for the first time exercised its legal right to arm-twist pharmaceutical companies to make available expensive, patented medicines at a lower cost, allowing the generic manufacture of a cancer drug owned by a foreign company.
We've made it easy for people to join this effort using a simple online tool, says KCA Chief Executive, Bill Bro, a 22-year kidney cancer survivor.
To evaluate the role of stereotactic radiosurgery (SRS) in the management of brain metastases from renal cell carcinoma.
The phenomenon reported by the researchers, known as the abscopal effect, occurs when localized radiation therapy delivered to a single tumor in a patient with advanced disease results in tumor disappearance outside of the irradiated area. Though the abscopal effect is extremely rare, it has been described in several cancers including melanoma, lymphoma, and kidney cancer.
Treatment with three relatively new "targeted" cancer drugs has been linked to a slightly elevated chance of fatal side effects.
Discovery of many genetic mutations within one cell may dash hopes for targeted treatments.
Therapeutic vaccines may prove both effective and directed as cancer treatments. One such product, being developed by Immatics Biotechnologies, is based on a selection of naturally presented tumour-associated peptides. Two versions are currently in the clinic IMA901 for renal cell carcinoma...
With six agents approved for metastatic renal cell carcinoma (mRCC) within the past 5 years, there has undoubtedly been progress in treating this disease. However, the goal of cure remains elusive, and the agents nearest approval (i.e., axitinib and tivozanib) abide by the same paradigm as existing drugs (i.e., inhibition of VEGF or mTOR signaling).
|Powered by NeonCRM|